Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients

The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the ins...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Mamdouh Ramadan [verfasserIn] Mohamed El-Wakil [verfasserIn] Shahera Shaaban [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy

Übergeordnetes Werk:	In: Egyptian Journal of Medical Research - Beni-Suef University, Faculty of Medicine, 2023, 1(2020), 1, Seite 43-54
Übergeordnetes Werk:	volume:1 ; year:2020 ; number:1 ; pages:43-54

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.21608/ejmr.2020.89043

Katalog-ID:	DOAJ079795935

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ079795935
003	DE-627
005	20230410112847.0
007	cr uuu---uuuuu
008	230310s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.21608/ejmr.2020.89043 \|2 doi
035			\|a (DE-627)DOAJ079795935
035			\|a (DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Mamdouh Ramadan \|e verfasserin \|4 aut
245	1	0	\|a Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS.
650		4	\|a disease-free survival (dfs)
650		4	\|a overall survival (os)
650		4	\|a neoadjuvant chemotherapy
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Mohamed El-Wakil \|e verfasserin \|4 aut
700	0		\|a Shahera Shaaban \|e verfasserin \|4 aut
773	0	8	\|i In \|t Egyptian Journal of Medical Research \|d Beni-Suef University, Faculty of Medicine, 2023 \|g 1(2020), 1, Seite 43-54 \|w (DE-627)1833777921 \|x 2682440X \|7 nnns
773	1	8	\|g volume:1 \|g year:2020 \|g number:1 \|g pages:43-54
856	4	0	\|u https://doi.org/10.21608/ejmr.2020.89043 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f \|z kostenfrei
856	4	0	\|u https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2682-4396 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2682-440X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 1 \|j 2020 \|e 1 \|h 43-54

Indexfelder

author_variant	m r mr m e w mew s s ss
matchkey_str	article:2682440X:2020----::agtdramntatzmbsontgetymrvlntrsriao
hierarchy_sort_str	2020
publishDate	2020
allfields	10.21608/ejmr.2020.89043 doi (DE-627)DOAJ079795935 (DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f DE-627 ger DE-627 rakwb eng Mamdouh Ramadan verfasserin aut Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS. disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy Medicine R Mohamed El-Wakil verfasserin aut Shahera Shaaban verfasserin aut In Egyptian Journal of Medical Research Beni-Suef University, Faculty of Medicine, 2023 1(2020), 1, Seite 43-54 (DE-627)1833777921 2682440X nnns volume:1 year:2020 number:1 pages:43-54 https://doi.org/10.21608/ejmr.2020.89043 kostenfrei https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f kostenfrei https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf kostenfrei https://doaj.org/toc/2682-4396 Journal toc kostenfrei https://doaj.org/toc/2682-440X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 1 43-54
spelling	10.21608/ejmr.2020.89043 doi (DE-627)DOAJ079795935 (DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f DE-627 ger DE-627 rakwb eng Mamdouh Ramadan verfasserin aut Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS. disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy Medicine R Mohamed El-Wakil verfasserin aut Shahera Shaaban verfasserin aut In Egyptian Journal of Medical Research Beni-Suef University, Faculty of Medicine, 2023 1(2020), 1, Seite 43-54 (DE-627)1833777921 2682440X nnns volume:1 year:2020 number:1 pages:43-54 https://doi.org/10.21608/ejmr.2020.89043 kostenfrei https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f kostenfrei https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf kostenfrei https://doaj.org/toc/2682-4396 Journal toc kostenfrei https://doaj.org/toc/2682-440X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 1 43-54
allfields_unstemmed	10.21608/ejmr.2020.89043 doi (DE-627)DOAJ079795935 (DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f DE-627 ger DE-627 rakwb eng Mamdouh Ramadan verfasserin aut Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS. disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy Medicine R Mohamed El-Wakil verfasserin aut Shahera Shaaban verfasserin aut In Egyptian Journal of Medical Research Beni-Suef University, Faculty of Medicine, 2023 1(2020), 1, Seite 43-54 (DE-627)1833777921 2682440X nnns volume:1 year:2020 number:1 pages:43-54 https://doi.org/10.21608/ejmr.2020.89043 kostenfrei https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f kostenfrei https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf kostenfrei https://doaj.org/toc/2682-4396 Journal toc kostenfrei https://doaj.org/toc/2682-440X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 1 43-54
allfieldsGer	10.21608/ejmr.2020.89043 doi (DE-627)DOAJ079795935 (DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f DE-627 ger DE-627 rakwb eng Mamdouh Ramadan verfasserin aut Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS. disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy Medicine R Mohamed El-Wakil verfasserin aut Shahera Shaaban verfasserin aut In Egyptian Journal of Medical Research Beni-Suef University, Faculty of Medicine, 2023 1(2020), 1, Seite 43-54 (DE-627)1833777921 2682440X nnns volume:1 year:2020 number:1 pages:43-54 https://doi.org/10.21608/ejmr.2020.89043 kostenfrei https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f kostenfrei https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf kostenfrei https://doaj.org/toc/2682-4396 Journal toc kostenfrei https://doaj.org/toc/2682-440X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 1 43-54
allfieldsSound	10.21608/ejmr.2020.89043 doi (DE-627)DOAJ079795935 (DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f DE-627 ger DE-627 rakwb eng Mamdouh Ramadan verfasserin aut Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS. disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy Medicine R Mohamed El-Wakil verfasserin aut Shahera Shaaban verfasserin aut In Egyptian Journal of Medical Research Beni-Suef University, Faculty of Medicine, 2023 1(2020), 1, Seite 43-54 (DE-627)1833777921 2682440X nnns volume:1 year:2020 number:1 pages:43-54 https://doi.org/10.21608/ejmr.2020.89043 kostenfrei https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f kostenfrei https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf kostenfrei https://doaj.org/toc/2682-4396 Journal toc kostenfrei https://doaj.org/toc/2682-440X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 1 43-54
language	English
source	In Egyptian Journal of Medical Research 1(2020), 1, Seite 43-54 volume:1 year:2020 number:1 pages:43-54
sourceStr	In Egyptian Journal of Medical Research 1(2020), 1, Seite 43-54 volume:1 year:2020 number:1 pages:43-54
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy Medicine R
isfreeaccess_bool	true
container_title	Egyptian Journal of Medical Research
authorswithroles_txt_mv	Mamdouh Ramadan @@aut@@ Mohamed El-Wakil @@aut@@ Shahera Shaaban @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	1833777921
id	DOAJ079795935
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079795935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410112847.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230310s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21608/ejmr.2020.89043</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079795935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mamdouh Ramadan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disease-free survival (dfs)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">overall survival (os)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neoadjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohamed El-Wakil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shahera Shaaban</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Egyptian Journal of Medical Research</subfield><subfield code="d">Beni-Suef University, Faculty of Medicine, 2023</subfield><subfield code="g">1(2020), 1, Seite 43-54</subfield><subfield code="w">(DE-627)1833777921</subfield><subfield code="x">2682440X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:43-54</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21608/ejmr.2020.89043</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2682-4396</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2682-440X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">43-54</subfield></datafield></record></collection>
author	Mamdouh Ramadan
spellingShingle	Mamdouh Ramadan misc disease-free survival (dfs) misc overall survival (os) misc neoadjuvant chemotherapy misc Medicine misc R Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients
authorStr	Mamdouh Ramadan
ppnlink_with_tag_str_mv	@@773@@(DE-627)1833777921
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	2682440X
topic_title	Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients disease-free survival (dfs) overall survival (os) neoadjuvant chemotherapy
topic	misc disease-free survival (dfs) misc overall survival (os) misc neoadjuvant chemotherapy misc Medicine misc R
topic_unstemmed	misc disease-free survival (dfs) misc overall survival (os) misc neoadjuvant chemotherapy misc Medicine misc R
topic_browse	misc disease-free survival (dfs) misc overall survival (os) misc neoadjuvant chemotherapy misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Egyptian Journal of Medical Research
hierarchy_parent_id	1833777921
hierarchy_top_title	Egyptian Journal of Medical Research
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1833777921
title	Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients
ctrlnum	(DE-627)DOAJ079795935 (DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f
title_full	Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients
author_sort	Mamdouh Ramadan
journal	Egyptian Journal of Medical Research
journalStr	Egyptian Journal of Medical Research
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	43
author_browse	Mamdouh Ramadan Mohamed El-Wakil Shahera Shaaban
container_volume	1
format_se	Elektronische Aufsätze
author-letter	Mamdouh Ramadan
doi_str_mv	10.21608/ejmr.2020.89043
author2-role	verfasserin
title_sort	targeted treatment trastuzumab is found to greatly improve long term survival of her2 breast cancer patients
title_auth	Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients
abstract	The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS.
abstractGer	The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS.
abstract_unstemmed	The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients
url	https://doi.org/10.21608/ejmr.2020.89043 https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf https://doaj.org/toc/2682-4396 https://doaj.org/toc/2682-440X
remote_bool	true
author2	Mohamed El-Wakil Shahera Shaaban
author2Str	Mohamed El-Wakil Shahera Shaaban
ppnlink	1833777921
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.21608/ejmr.2020.89043
up_date	2024-07-04T00:51:39.500Z
_version_	1803607657154609152
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079795935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410112847.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230310s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21608/ejmr.2020.89043</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079795935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJee6eb647f73848c39fa3d6b0a400c85f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mamdouh Ramadan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disease-free survival (dfs)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">overall survival (os)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neoadjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohamed El-Wakil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shahera Shaaban</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Egyptian Journal of Medical Research</subfield><subfield code="d">Beni-Suef University, Faculty of Medicine, 2023</subfield><subfield code="g">1(2020), 1, Seite 43-54</subfield><subfield code="w">(DE-627)1833777921</subfield><subfield code="x">2682440X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:43-54</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21608/ejmr.2020.89043</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ee6eb647f73848c39fa3d6b0a400c85f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ejmr.journals.ekb.eg/article_89043_9ab1075b69f36fe5062af32f53129aa2.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2682-4396</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2682-440X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">43-54</subfield></datafield></record></collection>
score	7.4026117

Nicht das Richtige dabei?

Schreiben Sie uns!

Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?